Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clarity PharmaceuticalsASX:CU6 +4.93%33 Cash Ratio is 10.14 as of Dec. 2025, which is 8% below its 10-year median of 11.00. GuruFocus rates ASX:CU6 with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,384 Biotechnology companies, Clarity Pharmaceuticals ranks better than 81% on this metric.
Clarity Pharmaceuticals has a Cash Ratio of 10.14. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Clarity Pharmaceuticals's Cash Ratio or its related term are showing as below:
ASX:CU6'
s Cash Ratio Range Over the Past 10 Years
Min: 7.76 Med: 11 Max: 57.9
Current: 10.14
During the past 4 years, Clarity Pharmaceuticals's highest Cash Ratio was 57.90. The lowest was 7.76. And the median was 11.00.
ASX:CU6's Cash Ratio is ranked better than 81% of 1384
companies
in the Biotechnology industry
Industry Median: 2.94
vs ASX:CU6: 10.14
Clarity Pharmaceuticals (ASX:CU6) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Clarity Pharmaceuticals Cash Ratio Related Terms
Clarity Pharmaceuticals Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CU6 vs VRTX, REGN, ALNY: Cash Ratio Comparison
For the Biotechnology subindustry, Clarity Pharmaceuticals's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clarity Pharmaceuticals Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clarity Pharmaceuticals's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Clarity Pharmaceuticals's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clarity Pharmaceuticals (ASX:CU6) has a Cash Ratio of 10.14 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Clarity Pharmaceuticals and its competitors. This is near median its historical median of 11.00. Over the past decade, Clarity Pharmaceuticals' Cash Ratio has ranged from 7.76 to 57.90. According to the industry distribution chart, Clarity Pharmaceuticals ranks #263 out of 1384 companies in the Biotechnology industry, placing it in the top 19%.
Is Clarity Pharmaceuticals' Cash Ratio too high?
Clarity Pharmaceuticals' current Cash Ratio of 10.14 is near median its 10-year median of 11.00. Over the past 10 years, this metric has ranged from a low of 7.76 to a high of 57.90. The Biotechnology industry median Cash Ratio is 2.94. Clarity Pharmaceuticals' value of 10.14 is 244.9% above this industry median. Based on the distribution chart, Clarity Pharmaceuticals ranks #263 out of 1384 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Clarity Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Clarity Pharmaceuticals' Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Clarity Pharmaceuticals ranks #263 out of 1384 companies for Cash Ratio. This places Clarity Pharmaceuticals in the top 19% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.94. Clarity Pharmaceuticals' value of 10.14 is 244.9% above this benchmark. Historically, Clarity Pharmaceuticals' own Cash Ratio has ranged from 7.76 to 57.90 over the past decade. While the company's 10-year median is 11.00 vs. the industry median of 2.94, Clarity Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.94, based on 1,384 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Clarity Pharmaceuticals's current Cash Ratio of 10.14 is 244.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Clarity Pharmaceuticals and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clarity Pharmaceuticals's current Cash Ratio is 10.14, which is near median its own 10-year median of 11.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clarity Pharmaceuticals stock overvalued right now?
Clarity Pharmaceuticals (ASX:CU6) has a current Cash Ratio of 10.14. The current Cash Ratio is 10.14, which is near median its 10-year median of 11.00 and 244.9% above the Biotechnology industry median of 2.94. Clarity Pharmaceuticals' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Clarity Pharmaceuticals (ASX:CU6), the current Cash Ratio is 10.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
33GF Score
Get the complete analysis for ASX:CU6
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CU6 has been successfully added to your 
